Monoamine oxidase B

Monoamine oxidase B
Monoamine oxidase B

PDB rendering based on 1gos.
Identifiers
Symbols MAOB; MGC26382
External IDs OMIM309860 MGI96916 HomoloGene20251 GeneCards: MAOB Gene
EC number 1.4.3.4
RNA expression pattern
PBB GE MAOB 204041 at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 4129 109731
Ensembl ENSG00000069535 ENSMUSG00000040147
UniProt P27338 Q14CG9
RefSeq (mRNA) NM_000898.4 NM_172778.2
RefSeq (protein) NP_000889.3 NP_766366.2
Location (UCSC) Chr X:
43.63 – 43.74 Mb
Chr X:
16.29 – 16.39 Mb
PubMed search [1] [2]

Monoamine oxidase B, also known as MAOB, is a protein that in humans is encoded by the MAOB gene.

The protein encoded by this gene belongs to the flavin monoamine oxidase family. It is an enzyme located in the mitochondrial outer membrane. It catalyzes the oxidative deamination of biogenic and xenobiotic amines and plays an important role in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. This protein preferentially degrades benzylamine and phenylethylamine.[1] Like MAOA, it also degrades dopamine.

Contents

Structure

Edmondson et al. described structural features of the human enzyme: it has a hydrophobic bipartite elongated cavity that (for the "open" conformation) occupies a combined volume close to 700 Å3. hMAO-A has a single cavity that exhibits a rounder shape and is larger in volume than the "substrate cavity" of hMAO-B.[2]

The first cavity of hMAO-B has been termed the entrance cavity (290 Å3), the second substrate cavity or active site cavity (~390 Å3) – between both an isoleucine199 side-chain serves as a gate. Depending on the substrate or bound inhibitor, it can exist in either an open or a closed form, which has been shown to be important in defining the inhibitor specificity of hMAO B. At the end of the substrate cavity is the FAD coenzyme with sites for favorable amine binding about the flavin involving two nearly parallel tyrosyl (398 and 435) residues that form what has been termed an aromatic cage.[2]

Differences between MAOA and MAOB

In general, Monoamine Oxidase A (MAOA) prefers to metabolize norepinephrine (NE), serotonin (5-HT), and Dopamine (DA) (and other less clinically relevant chemicals). Monoamine Oxidase B, on the other hand, prefers to metabolize Dopamine (DA) (and other less clinically relevant chemicals).The differences between the substrate selectivity of the two enzymes are utilized clinically when treating specific disorders: Monoamine Oxidase A inhibitors have been used in the treatment of depression, and Monoamine Oxidase B inhibitors are used in the treatment of Parkinson's Disease.[citation needed]

Selective inhibitors

Species-dependent divergences may hamper the extrapolation of inhibitor potencies.[3]

Reversible

Natural

Geiparvarin
(+)-Catechin

Synthetic

Structural formulae of high-affinity reversible MAO inhibitors selective for type B
3d model of compound 2D (Frédérick, 2006)[6]
3d model of compound 2 (Matos, 2011)[7]
3d model of compound 41 (Catto, 2006)[8]

Irreversible (covalent)


References

  1. ^ "Entrez Gene: MAOB monoamine oxidase B". http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=4129. 
  2. ^ a b Edmondson DE, Binda C, Mattevi A (2007). "STRUCTURAL INSIGHTS INTO THE MECHANISM OF AMINE OXIDATION BY MONOAMINE OXIDASES A AND B". Archives of Biochemistry and Biophysics 464 (2): 269–76. doi:10.1016/j.abb.2007.05.006. PMC 1993809. PMID 17573034. http://linkinghub.elsevier.com/retrieve/pii/S0003-9861(07)00252-4. 
  3. ^ a b c Novaroli L, Daina A, Favre E, et al. (October 2006). "Impact of species-dependent differences on screening, design, and development of MAO B inhibitors". Journal of Medicinal Chemistry 49 (21): 6264–72. doi:10.1021/jm060441e. PMID 17034132. 
  4. ^ Carotti A, Carrieri A, Chimichi S, Boccalini M, Cosimelli B, Gnerre C, Carotti A, Carrupt PA, Testa B (December 2002). "Natural and synthetic geiparvarins are strong and selective MAO-B inhibitors. Synthesis and SAR studies". Bioorg. Med. Chem. Lett. 12 (24): 3551–5. doi:10.1016/S0960-894X(02)00798-9. PMID 12443774. 
  5. ^ Uebelhack R, Franke L, Schewe HJ (September 1998). "Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava)". Pharmacopsychiatry 31 (5): 187–92. doi:10.1055/s-2007-979325. PMID 9832350. 
  6. ^ a b compound #2d, Frédérick R, Dumont W, Ooms F, Aschenbach L, Van der Schyf CJ, Castagnoli N, Wouters J, Krief A (June 2006). "Synthesis, structural reassignment, and biological activity of type B MAO inhibitors based on the 5H-indeno[1,2-c]pyridazin-5-one core". J. Med. Chem. 49 (12): 3743–7. doi:10.1021/jm051091j. PMID 16759116. 
  7. ^ a b compound #2, Matos MJ, Vazquez-Rodriguez S, Uriarte E, Santana L, Viña D (July 2011). "MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins". Bioorg. Med. Chem. Lett. 21 (14): 4224–7. doi:10.1016/j.bmcl.2011.05.074. PMID 21684743. 
  8. ^ a b compound #41, Catto M, Nicolotti O, Leonetti F, Carotti A, Favia AD, Soto-Otero R, Méndez-Alvarez E, Carotti A (2006). "Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches". Journal of Medicinal Chemistry 49 (16): 4912–25. doi:10.1021/jm060183l. PMID 16884303. 
  9. ^ Leonetti F, Capaldi C, Pisani L, Nicolotti O, Muncipinto G, Stefanachi A, Cellamare S, Caccia C, Carotti A (October 2007). "Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase". Journal of Medicinal Chemistry 50 (20): 4909–16. doi:10.1021/jm070725e. PMID 17824599. 
  10. ^ Carotti A, Catto M, Leonetti F, Campagna F, Soto-Otero R, Méndez-Alvarez E, Thull U, Testa B, Altomare C (November 2007). "Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives". Journal of Medicinal Chemistry 50 (22): 5364–71. doi:10.1021/jm070728r. PMID 17910428. 
  11. ^ Chimenti F, Fioravanti R, Bolasco A, et al. (May 2009). "Chalcones: a valid scaffold for monoamine oxidases inhibitors". J. Med. Chem. 52 (9): 2818–24. doi:10.1021/jm801590u. PMID 19378991. 
  12. ^ compound #21, Silvestri R, La Regina G, De Martino G, Artico M, Befani O, Palumbo M, Agostinelli E, Turini P (March 2003). "Simple, potent, and selective pyrrole inhibitors of monoamine oxidase types A and B". J. Med. Chem. 46 (6): 917–20. doi:10.1021/jm0256124. PMID 12620068. 
  13. ^ compound # (R)-8b, Chimenti F, Secci D, Bolasco A, Chimenti P, Granese A, Carradori S, Yáñez M, Orallo F, Sanna ML, Gallinella B, Cirilli R (September 2010). "Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines". J. Med. Chem. 53 (17): 6516–20. doi:10.1021/jm100120s. PMID 20715818. 
  14. ^ compound #18, Chimenti F, Maccioni E, Secci D, Bolasco A, Chimenti P, Granese A, Befani O, Turini P, Alcaro S, Ortuso F, Cardia MC, Distinto S (February 2007). "Selective inhibitory activity against MAO and molecular modeling studies of 2-thiazolylhydrazone derivatives". J. Med. Chem. 50 (4): 707–12. doi:10.1021/jm060869d. PMID 17253676. 
  15. ^ compound #3g, Chimenti F, Fioravanti R, Bolasco A, Manna F, Chimenti P, Secci D, Befani O, Turini P, Ortuso F, Alcaro S (February 2007). "Monoamine oxidase isoform-dependent tautomeric influence in the recognition of 3,5-diaryl pyrazole inhibitors". J. Med. Chem. 50 (3): 425–8. doi:10.1021/jm060868l. PMID 17266193. 
  16. ^ compound #(S)-1, Chimenti F, Maccioni E, Secci D, Bolasco A, Chimenti P, Granese A, Befani O, Turini P, Alcaro S, Ortuso F, Cirilli R, La Torre F, Cardia MC, Distinto S (November 2005). "Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)- pyrazole derivatives". J. Med. Chem. 48 (23): 7113–22. doi:10.1021/jm040903t. PMID 16279769. 
  17. ^ Mishra N, Sasmal D (April 2011). "Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation". Bioorg. Med. Chem. Lett. 21 (7): 1969–73. doi:10.1016/j.bmcl.2011.02.030. PMID 21377879. 
  18. ^ Matos MJ, Viña D, Janeiro P, Borges F, Santana L, Uriarte E (September 2010). "New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors". Bioorg. Med. Chem. Lett. 20 (17): 5157–60. doi:10.1016/j.bmcl.2010.07.013. PMID 20659799. 
  19. ^ Matos MJ, Viña D, Picciau C, Orallo F, Santana L, Uriarte E (September 2009). "Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors". Bioorg. Med. Chem. Lett. 19 (17): 5053–5. doi:10.1016/j.bmcl.2009.07.039. PMID 19628387. 
  20. ^ Matos MJ, Viña D, Quezada E, Picciau C, Delogu G, Orallo F, Santana L, Uriarte E (June 2009). "A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors". Bioorg. Med. Chem. Lett. 19 (12): 3268–70. doi:10.1016/j.bmcl.2009.04.085. PMID 19423346. 
  21. ^ compound #9, #12, Gaspar A, Reis J, Fonseca A, Milhazes N, Viña D, Uriarte E, Borges F (January 2011). "Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors". Bioorg. Med. Chem. Lett. 21 (2): 707–9. doi:10.1016/j.bmcl.2010.11.128. PMID 21194943. 
  22. ^ compound #9i, Manley-King CI, Bergh JJ, Petzer JP (January 2011). "Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues". Bioorg. Med. Chem. 19 (1): 261–74. doi:10.1016/j.bmc.2010.11.028. PMID 21134756. 
  23. ^ compound #5c, Manley-King CI, Bergh JJ, Petzer JP (August 2011). "Inhibition of monoamine oxidase by C5-substituted phthalimide analogues". Bioorg. Med. Chem. 19 (16): 4829–40. doi:10.1016/j.bmc.2011.06.070. PMID 21778064. 
  24. ^ Strydom B, Bergh JJ, Petzer JP (August 2011). "8-Aryl- and alkyloxycaffeine analogues as inhibitors of monoamine oxidase". Eur J Med Chem 46 (8): 3474–85. doi:10.1016/j.ejmech.2011.05.014. PMID 21621312. 
  25. ^ Strydom B, Malan SF, Castagnoli N, Bergh JJ, Petzer JP (February 2010). "Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues". Bioorg. Med. Chem. 18 (3): 1018–28. doi:10.1016/j.bmc.2009.12.064. PMID 20093036. 
  26. ^ Vlok N, Malan SF, Castagnoli N, Bergh JJ, Petzer JP (May 2006). "Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC)". Bioorg. Med. Chem. 14 (10): 3512–21. doi:10.1016/j.bmc.2006.01.011. PMID 16442801. 
  27. ^ Pretorius J, Malan SF, Castagnoli N, Bergh JJ, Petzer JP (September 2008). "Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues". Bioorganic & Medicinal Chemistry 16 (18): 8676–84. doi:10.1016/j.bmc.2008.07.088. PMID 18723354. 

Further reading


Wikimedia Foundation. 2010.

Игры ⚽ Нужно сделать НИР?

Look at other dictionaries:

  • Monoamine oxidase A — Ribbon diagram of an MAO A monomer, with FAD and clorgiline bound, oriented as if attached to the outer membrane of a mitochondrion …   Wikipedia

  • monoamine oxidase — n. MAO …   English World dictionary

  • Monoamine oxidase — MAO redirects here. For other uses, see Mao (disambiguation). Monoamine oxidase Identifiers EC number 1.4.3.4 CAS number …   Wikipedia

  • monoamine oxidase — SYN: amine oxidase (flavin containing). * * * monoamine oxidase n an enzyme that deaminates monoamines oxidatively and that functions in the nervous system by breaking down monoamine neurotransmitters * * * (MAO) an enzyme that catalyses the… …   Medical dictionary

  • monoamine oxidase — MAO an enzyme that catalyses the oxidation of a large variety of monoamines, including adrenaline, noradrenaline, and serotonin. Monoamine oxidase is found in most tissues, particularly the liver and nervous system. Drugs that act as inhibitors… …   The new mediacal dictionary

  • monoamine-oxidase inhibitor — noun One of a class of drugs that allow the build up of serotonin in the brain, used to treat severe depression (abbrev MAOI) • • • Main Entry: ↑monoamine …   Useful english dictionary

  • Monoamine oxidase — Monoamine oxydase Les monoamine oxydases (MAO) (EC 1.4.3.4) sont un groupe d enzymes intervenant dans le catabolisme de certaines hormones, de la sérotonine notamment oxydation des monoamines. On les trouve dans la membrane externe des… …   Wikipédia en Français

  • Monoamine oxidase inhibitor — MAOI redirects here. For the Easter Island statues, see Moai. Monoamine oxidase Monoamine oxidase inhibitors (MAOIs) are a class of antidepressant drugs prescribed for the treatment of depression. They are particularly effective in treating… …   Wikipedia

  • Monoamine oxidase inhibitor — One of a potent class of medications used to treat depression. Abbreviated MAOI. * * * monoamine oxidase inhibitor n any of various antidepressant drugs which increase the concentration of monoamines in the brain by inhibiting the action of… …   Medical dictionary

  • monoamine oxidase inhibitor — noun Medicine any of a group of antidepressant drugs which inhibit the activity of monoamine oxidase (so allowing accumulation of serotonin and noradrenaline in the brain) …   English new terms dictionary

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”